The APOLLO/LUNAR studies

In 2 pivotal Phase 3 studies, VYZULTA provided significantly greater IOP reduction from baseline compared with timolol 0.5%.1,2

UP TO

9.1-mmHg IOP reduction icon data point from APOLLO/LUNAR

IOP REDUCTIONfrom baseline1

Mean IOP reduction ranged from 7.5 mmHg to 9.1 mmHg in 9 time points through Month 3 (P<0.001).1,2*

>30%

MEAN DIURNAL IOP REDUCTION

across all tested time points3

>30%

MEAN DIURNAL IOP REDUCTION

across all tested time points3

At Month 3, the mean diurnal IOP reduction was 32% in both studies.†

Baseline mean diurnal IOP was 26.7 mmHg and 26.5 mmHg in APOLLO and 26.6 mmHg and 26.4 mmHg in LUNAR for VYZULTA and timolol 0.5%, respectively.1,2
STUDY DESIGN

In a pooled analysis, mean IOP was lower in VYZULTA patients compared with timolol 0.5% patients at Month 3 and stayed low through Month 12.4

tab one with line graph showing VYZULTA&reg; versus timolol in APOLLO and LUNAR pivotal studies
yellow down arrow icon with copy about IOP reduction data

VYZULTA provided consistent IOP lowering over a 12-month period.4

Patients who switched from timolol 0.5% to VYZULTA at Month 3 experienced additional IOP reductions.4

Most VYZULTA patients exceeded AAO IOP reduction targets of 20% to 30% from baseline5,6

Post Hoc Responder Analysis of APOLLO/LUNAR Pooled Data (N=562)6

tab two with bar chart of pooled post hoc data showing most VYZULTA&reg; patients exceeded AAO IOP reduction targets
POST HOC ANALYSIS

Baseline mean diurnal IOP was 26.7 mmHg and 26.5 mmHg in APOLLO and 26.6 mmHg and 26.4 mmHg in LUNAR for VYZULTA and timolol 0.5%, respectively.1,2

STUDY DESIGN
See what VYZULTA clinical trial results stood out to these optometrists.

*Vs 6.6 mmHg-8.0 mmHg for timolol 0.5%.1,2

†Vs 27% and 28% with timolol 0.5% in LUNAR and APOLLO, respectively.3

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information.

References: 1. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973. 2. Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259. 3. Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017;18(4):433-444. 4. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7-15. 5. Primary Open-Angle Glaucoma Preferred Practice Pattern. American Academy of Ophthalmology; 2020. 6. Peace JH, Vittitow JL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma: responder rates in phase 3 studies. Poster presented at: American Academy of Ophthalmology Meeting; October 15-18, 2016; Chicago, Illinois.

Expand

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent